Highly Potent Drugs

Formulating an ADC Development Solution

May 02, 2020

Many antibody-drug conjugate therapies are in the pipeline; however, only a handful have been approved. What are the bottlenecks?

Keeping Toxicity to a Minimum

March 02, 2020

Assays can provide a useful tool in determining the potential toxicity of drugs throughout the development cycle.

Best Practices in Handling HPAPIs

October 02, 2019

Establishing OEL data and ensuring appropriate engineering controls are crucial aspects of safe handling.

Majority of High-Containment CMO Facilities Located in 5EU and Switzerland, Notes GlobalData

August 15, 2019

The latest research from GlobalData has revealed that more than two-thirds (69%) of CMOs high-containment facilities are based in the top five European Union countries and Switzerland.

In Safe Hands

August 02, 2019

Pharmaceutical Technology Europe

Complex and potent molecules demand greater technical and regulatory expertise to ensure safe handling.

Lonza Expands HPAPI Capacity

June 17, 2019

Two additional production lines expand Lonza’s HPAPI capacity at Visp, Switzerland facility.

Enabling Technologies Advance Poorly Soluble Highly Potent APIs

June 02, 2019

Excipients and new processing techniques can make a real difference in the development of highly potent therapies.

Single-Use Containers for Sterile Transfer of Powders

April 17, 2019

The ChargePoint Single Use Passive and ChargeBag create a single-use system for contained and sterile transfer of pharmaceutical powders between process steps or facilities.

Strategic Screening for Solubility Solutions

March 02, 2019

Understanding the API, delivery mechanism, and excipient functionality is essential to solving drug solubility challenges.

Handle with Care

March 02, 2019

Bio/pharma companies facing new challenges in light of the increasing HPAPI market may benefit from outsourcing.